101
Views
9
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Characteristics and reference ranges of Insulin-Like Growth Factor-I measured with a commercially available immunoassay in 724 healthy adult Caucasians

, , , &
Pages 880-885 | Received 13 Mar 2009, Accepted 28 Jun 2009, Published online: 10 Dec 2009

References

  • Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13:113–70.
  • Clemmons DR. IGF-I assays: current assay methodologies and their limitations. Pituitary 2007; 10:121–8.
  • Ranke MB, Osterziel KJ, Schweizer R, Schuett B, Weber K, Robbel P, Vornwald A, Blumenstock G, Elmlinger MW. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays. Clin Chem Lab Med 2003; 41:1329–34.
  • Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 2007; 67:65–70.
  • Raymond I, Pedersen F, Busch-Sorensen M, Green A, Hildebrandt P. The Frederiksberg Heart Failure Study: rationale, design and methodology, with special emphasis on the sampling procedure for the study population and its comparison to the background population. Heart Drug 2002; 2:167–74.
  • Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van DJ, Juul A. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal 1999; 13:166–72.
  • Massart C, Poirier JY. Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta 2006; 373:176–9.
  • Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg PA, Bengtsson BA. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 1994; 41:351–7.
  • Brabant G, von zur MA, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003; 60:53–60.
  • Elmlinger MW, Kuhnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004; 42:654–64.
  • Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78; 1994:744–52.
  • Aimaretti G, Boschetti M, Corneli G, Gasco V, Valle D, Borsotti M, Rossi A, Barreca A, Fazzuoli L, Ferone D, Ghigo E, Minuto F. Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest 2008; 31:445–9.
  • Munzer T, Rosen CJ, Harman SM, Pabst KM, St CC, Sorkin JD, Blackman MR. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men. Am J Physiol Endocrinol Metab 2006; 290:E1006–13.
  • Hartog H, van der Graaf WT, Wesseling J, van der Veer E, Boezen HM. Measurement of insulin-like growth actor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. Clin Biochem 2008; 41:636–9.
  • Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev 2005; 14:727–30.
  • Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res 2006; 16:86–92.
  • Holt RI, Erotokritou-Mulligan I, Ridley SA, McHugh CM, Bassett EE, Cowan DA, Bartlett C, Sonksen PH. A determination of the pre-analytical storage conditions for insulin like growth factor-I and type III procollagen peptide. Growth Horm IGF Res 2009; 19:43–50.
  • Ranke MB, Feldt-Rasmussen U, Bang P, Baxter RC, Camacho-Hubner C, Clemmons DR, Juul A, Orskov H, Strasburger CJ. How should insulin-like growth factor I be measured? A consensus statement. Horm Res 2001; 55 Suppl. 2:106–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.